Adial Pharmaceuticals ( (ADIL) ) just unveiled an update.
Adial Pharmaceuticals announced that it will be engaging in business development meetings over the coming weeks and has updated its business development presentation, which includes forward-looking statements. The company stated that this information will not be filed under certain sections of the Securities Act and will not be incorporated into any SEC filings, highlighting the company’s focus on strategic growth initiatives and communication with stakeholders.
More about Adial Pharmaceuticals
YTD Price Performance: -3.77%
Average Trading Volume: 183,656
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $6.6M
Learn more about ADIL stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “Be the Leader You’ve Been Complaining For!” Paramount Stock (NASDAQ:PARA) Dips as Paramount Pulls Out of Politics
- Don’t “Get Rid of All Your Engine Designers”: Ford Stock (NYSE:F) Dips as it Brings Back a Big Name in Internal Combustion
- “Advanced Silicon Wafer Tests” Start; Intel Stock (NASDAQ:INTC) Slips